Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744052 | 0.80 | EGFR (0.53) | HPGDEGFRHTTL3MBTL1KMT2A | |
| SCHEMBL5862288 | 0.78 | PKM (0.53) | HPGDHTTKMT2AGAA | |
| SCHEMBL6744833 | 0.76 | POLB (0.48) | HPGDCA1CA2CA12CA9 | |
| SCHEMBL5862233 | 0.73 | — | — | |
| SCHEMBL156259 | 0.71 | CA2 (0.67) | CA1CA2CA12CA4CA6 | |
| SCHEMBL28696903 | 0.70 | KMT2A (0.42) | HPGDEGFRHTTL3MBTL1KMT2A | |
| SCHEMBL28212101 | 0.70 | KMT2A (0.42) | HPGDEGFRHTTL3MBTL1KMT2A | |
| SCHEMBL31717194 | 0.69 | PDK1 (0.45) | HPGDEGFRKMT2AGAA | |
| SCHEMBL31028687 | 0.69 | KMT2A (0.41) | HPGDCA1CA2CA12CA6 | |
| SCHEMBL5862245 | 0.68 | RAPGEF4 (0.42) | CA1CA2CA12CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030145-B2 | Pyridinyl derivatives for the treatment of depression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040209917-A1 | Pyridinyl derivatives for the treatment of depression | HARTZ RICHARD A (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209917-A1 | Pyridinyl derivatives for the treatment of depression | CRH, CRHR1, CRHR2 | HPGD 304/4885CA1 3665/4885CA2 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.